Scarica l'app Stockscreener
2.00
10.19%
0.185
Pre-mercato:
1.99
-0.01
-0.50%
Precedente Chiudi:
$1.815
Aprire:
$1.78
Volume 24 ore:
203.75K
Relative Volume:
0.03
Capitalizzazione di mercato:
$1.50M
Reddito:
-
Utile/perdita netta:
$-11.38M
Rapporto P/E:
-0.0721
EPS:
-27.73
Flusso di cassa netto:
$-12.72M
1 W Prestazione:
-11.11%
1M Prestazione:
+1,150%
6M Prestazione:
-34.43%
1 anno Prestazione:
+395.05%
Intervallo 1D:
$1.78
$2.20
Intervallo di 1 settimana:
$1.78
$2.283
Portata 52W:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Nome
Windtree Therapeutics Inc
Settore
Industria
Telefono
(215) 488-9300
Indirizzo
2600 KELLY ROAD, WARRINGTON, PA
Confronta WINT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
2.00 | 1.50M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.34 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.16 | 78.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.43 | 35.27B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
238.74 | 30.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.71 | 26.37B | 3.32B | -860.46M | -1.04B | -8.32 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-26 | Iniziato | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Borsa (WINT) Ultime notizie
FY2024 Earnings Forecast for WINT Issued By Zacks Small Cap - Defense World
Windtree Therapeutics Secures Patent for Istaroxime IV Formulation in Acute Heart Failure - MSN
Windtree (WINT) Sees Pre-Market Surge Following Key Patent Milestone - Stocks Telegraph
SponsoredImpartialComprehensive - Research Tree
Windtree Therapeutics (WINT) Shares Are Volatile: What's Going On? - Benzinga
WINT: Advancing Lead Asset; Leveraging Strategic M&A to Potentially Shorten Timeline to Revenue Generation – Initiating Coverage - Yahoo Finance
WINTWindtree Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Windtree's Heart Failure Treatment Gains Critical Patent ProtectionWhat This Means for AHF Patients - StockTitan
Windtree Therapeutics Files Patent Application in India for Istaroxime, Advancing Arrhythmia Treatment - MSN
Discovery Laboratories Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015 - Marketscreener.com
Comparing Senti Biosciences (NASDAQ:SNTI) and Windtree Therapeutics (NASDAQ:WINT) - Defense World
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Drop in Short Interest - Defense World
Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India - The Manila Times
Windtree's Cardiac Drug Patent Filing Targets India's Massive MarketPhase 3 Trials on Horizon - StockTitan
Windtree Therapeutics Announces Reverse Stock Split to Maintain Nasdaq Compliance - MSN
Inhibikase Therapeutics (NYSE:IKT) vs. Windtree Therapeutics (NASDAQ:WINT) Critical Survey - Defense World
Windtree Therapeutics, Inc. Announces Reverse Stock Split - GlobeNewswire
Windtree Therapeutics approves 1-for-50 reverse stock split - MSN
Windtree Therapeutics Approves 1-for-50 Reverse Stock Split; Shares Fall Pre-Bell -February 18, 2025 at 09:35 am EST - Marketscreener.com
Windtree Therapeutics Announces Reverse Stock Split Approval - TipRanks
Windtree Therapeutics approves 1-for-50 reverse stock split By Investing.com - Investing.com South Africa
Strategic 1:50 Reverse Split: Windtree's Bold Move to Secure Nasdaq Future - StockTitan
Windtree Therapeutics Highlights Promising Phase 2b Results for Istaroxime - MSN
Windtree Therapeutics, Inc. (NASDAQ:WINT) Sees Significant Drop in Short Interest - Defense World
Windtree reports positive Phase 2b study on heart failure therapy - MSN
Windtree reports positive Phase 2b study on heart failure therapy By Investing.com - Investing.com South Africa
Windtree Announces Special Late-Breaking Clinical Science - GlobeNewswire
Breakthrough Heart Failure Drug Shows Remarkable Safety Profile in Latest Clinical Trial - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
The -95.92% Simple Moving Average of Windtree Therapeutics Inc’s (WINT) Stock in the Past 200 Days - The News Heater
Market Watch Highlights: Windtree Therapeutics Inc (WINT) Ends on an Downturn Note at 0.12 - The Dwinnex
Windtree Therapeutics Inc (NASDAQ: WINT) Stock Dropped -60.95% Over A Month – Any Room To Run? - Marketing Sentinel
Windtree Therapeutics enacts reverse stock split, expands equity plan - MSN
WINT: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
WINT (Windtree Therapeutics Inc) may reap gains as insiders became active recently - Knox Daily
It makes sense and dollars to buy Windtree Therapeutics Inc (WINT) stock - SETE News
Windtree Therapeutics enacts reverse stock split, expands equity plan By Investing.com - Investing.com Australia
This morning’s top pick is Windtree Therapeutics Inc (NASDAQ:WINT) - US Post News
Short Interest in Windtree Therapeutics, Inc. (NASDAQ:WINT) Rises By 72.4% - Defense World
Windtree Therapeutics adjusts Series C Preferred Stock terms - MSN
What Did We Find About Insider Trading At Windtree Therapeutics Inc (NASDAQ: WINT)? - Stocks Register
Windtree Therapeutics Announces Offer to Reduce Conversion Price of Series C Preferred Stock - Defense World
Windtree Therapeutics Inc Azioni (WINT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.14%
2.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):